転移性尿路上皮がん患者における通常の免疫療法治療であるアベルマブへの抗がん剤カボザンチニブの追加試験、MAIN-CAV 試験
MAIN-CAV: 転移性尿路上皮がん患者における第一選択のプラチナベースの化学療法後の維持カボザンチニブおよびアベルマブ vs 維持アベルマブの第 III 相無作為化試験
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing.
調査の概要
状態
条件
- 進行性膀胱尿路上皮がん
- 進行性尿管 尿路上皮がん
- 転移性膀胱尿路上皮がん
- 転移性腎盂尿路上皮がん
- 転移性尿管 尿路上皮がん
- 転移性尿道尿路上皮がん
- ステージ III 膀胱がん AJCC v8
- ステージ III の腎盂がん AJCC v8
- ステージ III 尿管がん AJCC v8
- ステージ III 尿道がん AJCC v8
- ステージ IV 膀胱がん AJCC v8
- ステージ IV の腎盂がん AJCC v8
- ステージ IV 尿管がん AJCC v8
- ステージ IV 尿道がん AJCC v8
- 進行性腎盂尿路上皮がん
- 進行性尿道尿路上皮がん
- ステージ III の腎盂および尿管がん AJCC v8
- ステージ IV の腎盂および尿管がん AJCC v8
詳細な説明
PRIMARY OBJECTIVE:
I. To evaluate the effect of cabozantinib (cabozantinib S-malate) in combination with avelumab on overall survival (OS) compared to avelumab alone in patients with metastatic urothelial cancer (mUC) who did not progress during first-line platinum-based chemotherapy therapy, i.e. patients who had complete response (CR), partial response (PR) or stable disease (SD) after completion of first line platinum-based chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate the effect of cabozantinib in combination with avelumab on progression-free survival (PFS) compared to avelumab alone for maintenance treatment following initial first-line treatment in patients who had a CR, PR or SD upon completion of first-line platinum-based chemotherapy.
II. To evaluate the safety and tolerability of cabozantinib in combination with avelumab in mUC compared to avelumab alone for maintenance treatment following initial first-line treatment in patients who had a CR, PR or SD upon completion of first-line platinum-based chemotherapy.
III. To evaluate activity of cabozantinib in combination with avelumab based on Response Evaluation Criteria in Solid Tumors (RECIST) compared to avelumab alone for maintenance treatment following initial first-line treatment in patients who had a CR, PR or SD upon completion of first-line platinum-based chemotherapy.
IV. Results of the primary analysis will be examined for consistency, while accounting for the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
V. To evaluate the activity of cabozantinib in combination with avelumab compared to avelumab alone based on PD-L1 status of patients' tumors.
QUALITY OF LIFE (QOL) OBJECTIVES:
I. To compare quality-adjusted survival between patients randomized to receive cabozantinib and avelumab versus (vs.) avelumab alone using the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).
II. To compare patient-reported fatigue as assessed by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue 4a from baseline through 12 months between patients randomized to receive cabozantinib and avelumab vs. avelumab alone.
III. To compare patient-reported global health status/quality of life as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 from baseline through 12 months between patients randomized to receive cabozantinib and avelumab vs. avelumab alone.
IV. To compare scale scores of the EORTC QLQ-Bladder Cancer Muscle-Invasive (BLM)30 (urinary symptoms, urostomy problems, catheter problems, future perspectives, abdominal bloating and flatulence, body image, sexual function) at 3, 6, 12, 18, and 24 months between patients randomized to receive cabozantinib and avelumab vs. avelumab alone.
V. To compare scale scores of the EORTC QLQ-C30 (global health status/quality of life; physical, role, emotional, cognitive, and social function; symptoms) at 3, 6, 12, 18, and 24 months between patients randomized to receive cabozantinib and avelumab vs. avelumab alone.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive avelumab intravenously (IV) over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo computed tomography (CT) or magnetic resonance imaging (MRI) and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated.
ARM B: Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated.
After completion of study treatment, patients are followed every 30 days through 90 days, then every 3 months for 5 years.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- Mayo Clinic Hospital in Arizona
-
-
California
-
Auburn、California、アメリカ、95602
- Sutter Auburn Faith Hospital
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Fremont、California、アメリカ、94538
- Palo Alto Medical Foundation-Fremont
-
Modesto、California、アメリカ、95355
- Memorial Medical Center
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto、California、アメリカ、94301
- Palo Alto Medical Foundation Health Care
-
Roseville、California、アメリカ、95661
- Sutter Roseville Medical Center
-
Sacramento、California、アメリカ、95816
- Sutter Medical Center Sacramento
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco、California、アメリカ、94115
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz、California、アメリカ、95065
- Palo Alto Medical Foundation-Santa Cruz
-
Sunnyvale、California、アメリカ、94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo、California、アメリカ、94589
- Sutter Solano Medical Center/Cancer Center
-
-
Delaware
-
Millville、Delaware、アメリカ、19967
- Beebe South Coastal Health Campus
-
Newark、Delaware、アメリカ、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、アメリカ、19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach、Delaware、アメリカ、19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville、Florida、アメリカ、32224-9980
- Mayo Clinic in Florida
-
Weston、Florida、アメリカ、33331
- Cleveland Clinic-Weston
-
-
Illinois
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Barrington、Illinois、アメリカ、60010
- Advocate Good Shepherd Hospital
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60657
- Advocate Illinois Masonic Medical Center
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Crystal Lake、Illinois、アメリカ、60014
- AMG Crystal Lake - Oncology
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
DeKalb、Illinois、アメリカ、60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、アメリカ、61021
- Illinois CancerCare-Dixon
-
Downers Grove、Illinois、アメリカ、60515
- Advocate Good Samaritan Hospital
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Elgin、Illinois、アメリカ、60123
- Advocate Sherman Hospital
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Geneva、Illinois、アメリカ、60134
- Northwestern Medicine Cancer Center Delnor
-
Hazel Crest、Illinois、アメリカ、60429
- Advocate South Suburban Hospital
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Lake Forest、Illinois、アメリカ、60045
- Northwestern Medicine Lake Forest Hospital
-
Libertyville、Illinois、アメリカ、60048
- Condell Memorial Hospital
-
Libertyville、Illinois、アメリカ、60048
- AMG Libertyville - Oncology
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Oak Lawn、Illinois、アメリカ、60453-2699
- Advocate Christ Medical Center
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge、Illinois、アメリカ、60068
- Advocate Lutheran General Hospital
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Rockford、Illinois、アメリカ、61114
- UW Health Carbone Cancer Center Rockford
-
Shiloh、Illinois、アメリカ、62269
- Memorial Hospital East
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington、Illinois、アメリカ、61571
- Illinois CancerCare - Washington
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- Northwest Cancer Center - Crown Point
-
Dyer、Indiana、アメリカ、46311
- Northwest Oncology LLC
-
Hobart、Indiana、アメリカ、46342
- Northwest Cancer Center - Hobart
-
Hobart、Indiana、アメリカ、46342
- Saint Mary Medical Center
-
Indianapolis、Indiana、アメリカ、46312
- Saint Catherine Hospital
-
Munster、Indiana、アメリカ、46321
- The Community Hospital
-
Munster、Indiana、アメリカ、46321
- Women's Diagnostic Center - Munster
-
Valparaiso、Indiana、アメリカ、46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Boone、Iowa、アメリカ、50036
- McFarland Clinic - Boone
-
Fort Dodge、Iowa、アメリカ、50501
- McFarland Clinic - Trinity Cancer Center
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson、Iowa、アメリカ、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、アメリカ、50158
- McFarland Clinic - Marshalltown
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- Baptist Health Louisville
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Worcester、Massachusetts、アメリカ、01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek、Michigan、アメリカ、49017
- Bronson Battle Creek
-
Brighton、Michigan、アメリカ、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton、Michigan、アメリカ、48114
- Trinity Health Medical Center - Brighton
-
Canton、Michigan、アメリカ、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton、Michigan、アメリカ、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、アメリカ、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea、Michigan、アメリカ、48118
- Chelsea Hospital
-
Clarkston、Michigan、アメリカ、48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston、Michigan、アメリカ、48346
- Newland Medical Associates-Clarkston
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Flint、Michigan、アメリカ、48503
- Genesee Hematology Oncology PC
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Flint、Michigan、アメリカ、48503
- Cancer Hematology Centers - Flint
-
Grand Rapids、Michigan、アメリカ、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49009
- Beacon Kalamazoo Cancer Center
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb、Michigan、アメリカ、48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Muskegon、Michigan、アメリカ、49444
- Trinity Health Muskegon Hospital
-
Norton Shores、Michigan、アメリカ、49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Pontiac、Michigan、アメリカ、48341
- Hope Cancer Center
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac、Michigan、アメリカ、48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Reed City、Michigan、アメリカ、49677
- Corewell Health Reed City Hospital
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Wyoming、Michigan、アメリカ、49519
- University of Michigan Health - West
-
Ypsilanti、Michigan、アメリカ、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti、Michigan、アメリカ、48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Bemidji、Minnesota、アメリカ、56601
- Sanford Joe Lueken Cancer Center
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott-Northwestern Hospital
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
Saint Cloud、Minnesota、アメリカ、56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Willmar、Minnesota、アメリカ、56201
- Rice Memorial Hospital
-
-
Missouri
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
City of Saint Peters、Missouri、アメリカ、63376
- Siteman Cancer Center at Saint Peters Hospital
-
Columbia、Missouri、アメリカ、65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Creve Coeur、Missouri、アメリカ、63141
- Siteman Cancer Center at West County Hospital
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital of Kansas City
-
Lee's Summit、Missouri、アメリカ、64086
- Saint Luke's East - Lee's Summit
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63129
- Siteman Cancer Center-South County
-
St Louis、Missouri、アメリカ、63136
- Siteman Cancer Center at Christian Hospital
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89102
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、アメリカ、89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Concord、New Hampshire、アメリカ、03301
- New Hampshire Oncology Hematology PA-Concord
-
Manchester、New Hampshire、アメリカ、03103
- Solinsky Center for Cancer Care
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- Memorial Sloan Kettering Basking Ridge
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Middletown、New Jersey、アメリカ、07748
- Memorial Sloan Kettering Monmouth
-
Montvale、New Jersey、アメリカ、07645
- Memorial Sloan Kettering Bergen
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
Paterson、New Jersey、アメリカ、07503
- Saint Joseph's Regional Medical Center
-
Summit、New Jersey、アメリカ、07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
Las Cruces、New Mexico、アメリカ、88011
- Memorial Medical Center-Las Cruces
-
-
New York
-
Commack、New York、アメリカ、11725
- Memorial Sloan Kettering Commack
-
Elmira、New York、アメリカ、14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Glens Falls、New York、アメリカ、12801
- Glens Falls Hospital
-
Harrison、New York、アメリカ、10604
- Memorial Sloan Kettering Westchester
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
Oswego、New York、アメリカ、13126
- Upstate Cancer Center at Oswego
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
Syracuse、New York、アメリカ、13215
- SUNY Upstate Medical Center-Community Campus
-
Uniondale、New York、アメリカ、11553
- Memorial Sloan Kettering Nassau
-
Verona、New York、アメリカ、13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte、North Carolina、アメリカ、28262
- Atrium Health University City/LCI-University
-
Charlotte、North Carolina、アメリカ、28211
- Levine Cancer Institute-SouthPark
-
Charlotte、North Carolina、アメリカ、28277
- Levine Cancer Institute-Ballantyne
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Concord、North Carolina、アメリカ、28025
- Atrium Health Cabarrus/LCI-Concord
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Lincolnton、North Carolina、アメリカ、28092
- Atrium Health Lincoln/LCI-Lincolnton
-
Shelby、North Carolina、アメリカ、28150
- Atrium Health Cleveland/LCI-Cleveland
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Sanford Bismarck Medical Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44307
- Cleveland Clinic Akron General
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Dayton、Ohio、アメリカ、45415
- Miami Valley Hospital North
-
Dayton、Ohio、アメリカ、45415
- Dayton Physician LLC - Englewood
-
Dayton、Ohio、アメリカ、45409
- Premier Blood and Cancer Center
-
Franklin、Ohio、アメリカ、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville、Ohio、アメリカ、45331
- Miami Valley Cancer Care and Infusion
-
Kettering、Ohio、アメリカ、45429
- Kettering Medical Center
-
Mansfield、Ohio、アメリカ、44906
- Cleveland Clinic Cancer Center Mansfield
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Sandusky、Ohio、アメリカ、44870
- North Coast Cancer Care
-
Strongsville、Ohio、アメリカ、44136
- Cleveland Clinic Cancer Center Strongsville
-
Toledo、Ohio、アメリカ、43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy、Ohio、アメリカ、45373
- Upper Valley Medical Center
-
Warrensville Heights、Ohio、アメリカ、44122
- South Pointe Hospital
-
Wooster、Ohio、アメリカ、44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Gresham、Oregon、アメリカ、97030
- Legacy Mount Hood Medical Center
-
Portland、Oregon、アメリカ、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin、Oregon、アメリカ、97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Harrisburg、Pennsylvania、アメリカ、17111
- Penn State Health Medical Group - Andrews Patel Hematology/Oncology East
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Philadelphia、Pennsylvania、アメリカ、19148
- Jefferson Methodist Hospital
-
-
South Carolina
-
Boiling Springs、South Carolina、アメリカ、29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Easley、South Carolina、アメリカ、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、アメリカ、29650
- Prisma Health Cancer Institute - Greer
-
Rock Hill、South Carolina、アメリカ、29732
- Levine Cancer Institute-Rock Hill
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Aberdeen、South Dakota、アメリカ、57401
- Avera Cancer Institute-Aberdeen
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Regional Hospital
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
Yankton、South Dakota、アメリカ、57078
- Avera Cancer Institute at Yankton
-
-
Tennessee
-
Alcoa、Tennessee、アメリカ、37701
- University Cancer Specialists - Alcoa
-
Knoxville、Tennessee、アメリカ、37920
- University of Tennessee - Knoxville
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、アメリカ、75237
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth、Texas、アメリカ、76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Richardson、Texas、アメリカ、75080
- UT Southwestern Clinical Center at Richardson/Plano
-
-
Virginia
-
Mechanicsville、Virginia、アメリカ、23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian、Virginia、アメリカ、23114
- Bon Secours Saint Francis Medical Center
-
Richmond、Virginia、アメリカ、23235
- VCU Massey Cancer Center at Stony Point
-
Richmond、Virginia、アメリカ、23229
- Virginia Cancer Institute
-
Richmond、Virginia、アメリカ、23226
- Bon Secours Saint Mary's Hospital
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
South Hill、Virginia、アメリカ、23970
- VCU Community Memorial Health Center
-
Winchester、Virginia、アメリカ、22601
- Shenandoah Oncology PC
-
-
Washington
-
Renton、Washington、アメリカ、98055
- Valley Medical Center
-
Vancouver、Washington、アメリカ、98686
- Legacy Salmon Creek Hospital
-
Vancouver、Washington、アメリカ、98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Burlington、Wisconsin、アメリカ、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown、Wisconsin、アメリカ、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、アメリカ、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、アメリカ、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、アメリカ、53142
- Aurora Cancer Care-Kenosha South
-
Marinette、Wisconsin、アメリカ、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Menomonee Falls、Wisconsin、アメリカ、53051
- Froedtert Menomonee Falls Hospital
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oak Creek、Wisconsin、アメリカ、53154
- Drexel Town Square Health Center
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh、Wisconsin、アメリカ、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、アメリカ、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、アメリカ、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、アメリカ、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Waukesha、Wisconsin、アメリカ、53188
- ProHealth Waukesha Memorial Hospital
-
Wauwatosa、Wisconsin、アメリカ、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
West Bend、Wisconsin、アメリカ、53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon、Saskatchewan、カナダ、S7N 4H4
- Saskatoon Cancer Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Histologically or cytologically-confirmed diagnosis of advanced or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell and mixed transitional/non-transitional cell histologies except for small-cell histology), including N3 only disease prior to start of first-line platinum-based chemotherapy
-
Prior first-line treatment must have consisted of 4-6 cycles of 1st-line therapy (platinum-based chemotherapy; gemcitabine-cisplatin, gemcitabine-carboplatin, methotrexate, vinblastine, doxorubicin and cisplatin [MVAC] or dose-dense [dd]MVAC)
-
No more than 1 line of prior chemotherapy for metastatic or locally advanced disease (neoadjuvant or adjuvant chemotherapy will be allowed if given 12 or more months prior to registration)
-
Tumor objective response of CR, PR, or SD upon completion of first line platinum-based chemotherapy by treating physician's assessment
-
The last dose of first-line chemotherapy must have been received no less than 3 weeks, and no more than 10 weeks, prior to randomization in the present study
-
No prior immunotherapy with IL-2, IFN-alpha, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects
-
Women of childbearing potential must have a negative pregnancy test =< 14 days prior to registration.
- Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason
-
No use of immunosuppressive medication within 7 days prior to randomization except:
- Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection);
- Systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent;
- Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with diabetes type I, vitiligo, psoriasis, or hypo or hyperthyroid disease not requiring immunosuppressive treatment are eligible
-
None of the following:
-
Active autoimmune disease that might deteriorate when receiving the anti PD-L1 agent, avelumab.
-
No known symptomatic central nervous system (CNS) metastases. Patients with previously diagnosed CNS metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to randomization, have discontinued corticosteroid treatment for at least 2 weeks, and are neurologically stable. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility.
-
No major surgery within 4 weeks prior to randomization. Subjects must have complete wound healing from surgery before randomization. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
-
No palliative radiotherapy within 48 hours prior to patient randomization.
-
No hemoptysis of ≥ 0.5 teaspoon (2.5 mL) of red blood, clinically significant hematuria, hematemesis, coagulopathy, or other history of significant bleeding (eg. Pulmonary hemorrhage) within 3 months before randomization.
-
No known cavitating pulmonary lesion(s) or known endobronchial disease manifestation.
-
No administration of a live, attenuated vaccine within 30 days prior to randomization. The use of inactivated (killed) vaccines for the prevention of infectious disease is permitted. The use of COVID-19 vaccines is permitted.
-
No uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
-
Cardiovascular disorders including:
- Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.
- Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
- The patient has a known history of corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms and confirmed by electrocardiogram (ECG) within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility in this regard.
- Any history of congenital long QT syndrome.
- Stroke, transient ischemic attack (TIA), myocardial infarction, or other symptomatic ischemic event or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism [DVT/PE]) within 6 months before randomization. Subjects with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if asymptomatic and stable at screening and treated with low molecular weight heparin (LMWH) or the direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban for at least 1 week before randomization. Non-symptomatic white matter disease in the brain is acceptable.
-
No significant gastrointestinal disorders, particularly those associated with a high risk of perforation or fistula formation including unresolved active peptic ulcer disease, cholecystitis, diverticultis, symptomatic cholangitis or appendicitis, or malabsorption syndrome within 28 days of randomization.
-
No other clinically significant disorders such as:
- Any active infection requiring systemic treatment within 14 days before randomization. Subjects receiving oral (including prophylactic) antibiotics with no symptoms of infection at randomization are eligible.
- Serious non-healing wound/ulcer/bone fracture within 28 days before randomization
- History of organ or allogeneic stem cell transplant
-
No persisting toxicity related to prior therapy grade > 2 constituting a safety risk based on the investigator's judgment.
-
No diagnosis of any other malignancy within 3 years prior to randomization, except for locally curable cancers that have been adequately treated such as basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, Gleason < 7 prostate cancer on surveillance without any plans for treatment intervention (eg, surgery, radiation, or castration), or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms and no indication for treatment.
-
No concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel).
-
Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
-
-
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
-
Platelet count >= 100,000/mm^3
-
Hemoglobin >= 8 g/dL
-
Calculated (Calc.) creatinine clearance >= 30 mL/min using the Cockcroft-Gault equation
-
Total serum bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN for patients with liver metastases or Gilbert's disease)
-
Urine protein creatinine (UPC) ratio =< 1 or 24-hour protein < 1 g
-
Physicians should consider whether any of the following may render the patient inappropriate for this protocol:
- Psychiatric illness which would prevent the patient from giving informed consent.
- Uncontrolled medical conditions which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
- Patients who cannot swallow oral formulations of the agent(s).
In addition:
- Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Include as applicable: Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom).
- Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and or steroids equivalent to < 10 mg prednisone daily, not on immunosuppressive medications and patients with positive serology are eligible. Patients with vitiligo, endocrine deficiencies including hypo or hyper thyroid disease managed with replacement, diabetes type 1 are eligible.
- Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the study and continue for 4 months after the last dose of study drugs, even if oral contraceptives are also used.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm A (avelumab)
Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated. |
Ancillary studies
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo bone scan
他の名前:
Given IV
他の名前:
Undergo collection of blood and urine samples
他の名前:
|
|
実験的:Arm B (avelumab, cabozantinib)
Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated. |
Ancillary studies
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Ancillary studies Given PO
他の名前:
Undergo bone scan
他の名前:
Given IV
他の名前:
Undergo collection of blood and urine samples
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS)
時間枠:Time from randomization until death due to any cause, assessed up to 5 years
|
Subgroup analyses will be done using a stratified Cox model that includes the treatment arm assignment as an explanatory variable and a separate model will be generated for each level for the subgroup of interest. |
Time from randomization until death due to any cause, assessed up to 5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival (PFS)
時間枠:Time from randomization until disease progression as assessed by the treating physician using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, assessed up to 5 years
|
A stratified Cox model will be used to compare the outcomes between the two treatment groups. The subgroup analyses will be done using a stratified Cox model that includes the treatment arm assignment as an explanatory variable and a separate model will be generated for each level for the subgroup of interest. |
Time from randomization until disease progression as assessed by the treating physician using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, assessed up to 5 years
|
|
Tumor response
時間枠:Up to 5 years
|
Will be defined as a complete response or partial response (PR) as measured with Immune-Modified RECIST. Will be compared between the arms using a Mantel-Haenszel test (that accounts for the randomization stratification factors) comparing the response rates between the two treatment arms. This analysis will only include patients who had a PR or stable disease (SD) response to first-line therapy. An additional analysis will be conducted using logistic regression analysis that includes treatment arm and any baseline variables that are imbalanced between the arms as explanatory variable. |
Up to 5 years
|
|
Incidence of adverse events (AE)
時間枠:Up to 5 years
|
Will be assessed by Common Terminology Criteria for Adverse Events 5.0. Will be summarized with frequencies and relative frequencies. The maximum grade for an AE will be recorded for each patient by treatment arm. The number (percent) of patients that experience each observed adverse event will be summarized by treatment arm. In addition, the proportion of patients that experience a grade 3+, grade 4+, and grade 5 adverse event will be summarized as the number and percent of patients by treatment arm. The primary summary will be regardless of attribution. Will also do an analogous summary for the adverse events that were deemed at least possibly related to treatment. |
Up to 5 years
|
協力者と研究者
捜査官
- 主任研究者:Shilpa Gupta、Alliance for Clinical Trials in Oncology
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2021-11166
- U10CA180821 (米国 NIH グラント/契約)
- NCI-2021-11166 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- A032001 (その他の識別子:CTEP)
- A032001 (その他の識別子:Alliance for Clinical Trials in Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。